Biotechnology News and Research

RSS

Soligenix reports positive results from preclinical studies of vaccine thermostabilization technology

Soligenix, Inc., a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

6 Feb 2012

Sandoz sends Remodulin Paragraph IV Notice Letter to United Therapeutics

United Therapeutics Corporation today announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz Inc. advising that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration requesting approval to market a generic version of the 10 mg/mL strength of Remodulin (treprostinil) injection.

6 Feb 2012

BioLineRx, Genoscience and RFS Pharma enter agreement for BL-8030 Hepatitis C treatment

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

6 Feb 2012

EntreMed receives $9.3 million in strategic financing

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received approximately $9.3 million in strategic financing, as previously announced on January 23, 2012.

6 Feb 2012

Exelixis reports preliminary data from cabozantinib phase 1b trial on RCC

Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma (RCC) participating in an ongoing phase 1b trial of cabozantinib.

3 Feb 2012

Merck Serono enters development agreement with Threshold for hypoxia-targeted drug

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

3 Feb 2012

The Mann Group and MannKind enter stock purchase agreement

MannKind Corporation today announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind's chief executive officer and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group.

3 Feb 2012

Scientists discover new mechanisms by which RNA drugs can control gene activity

Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.

3 Feb 2012

MannKind prices underwritten public offering of 31,250,000 units of common stock

MannKind Corporation today announced the pricing of an underwritten public offering of 31,250,000 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.6 of a share of its common stock.

3 Feb 2012

Pros and cons of routine school BMI screening

The value of routine body mass index (BMI) screening in schools has been a topic of ongoing controversy. An expert Roundtable Discussion in the current issue of Childhood Obesity, a peer-reviewed journal published by Mary Ann Liebert, Inc., debates the pros and cons of routine BMI screening in the school setting, discusses the most recent data, and explores when and for what purpose BMI screening results should be shared with parents and the potential benefits.

2 Feb 2012

ImmunoCellular receives U.S. patent allowance for cancer stem cell treatment

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company's method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells.

2 Feb 2012

Sartorius consolidated sales revenue increases to 733.1M for fiscal 2011

Sartorius, a leading international laboratory and process equipment provider, grew dynamically yet again in 2011 and significantly expanded its profitability. Both Group divisions reported highs in sales revenue and earnings.

From Sartorius 2 Feb 2012

Wyatt Technology Instruments employed to develop alternative materials to silicone breast implants

Wyatt Technology Corporation today announced that Professor Judit E. Puskas at the University of Akron has developed a system using its instrumentation that will also help to solve a prevalent and particularly controversial material science challenge. The researchers are employing the multi detector system to develop alternative materials to silicone breast implants. This development will be welcomed by many as faulty Poly Implant Prothèse (PIP) implants are causing global concern about implant safety, and as a result, alternative materials are sought.

1 Feb 2012

New light on how superbugs become resistant to antibiotics

Scientists have shed new light on the way superbugs such as MRSA are able to become resistant to treatment with antibiotics

1 Feb 2012

Omeros, BioMed sign new 15-year lease agreement

BioMed Realty Trust, Inc. announced today the signing of a new 15-year lease with Omeros Corporation for BioMed's Waterfront Research Center property located in Seattle, Washington.

1 Feb 2012

CartiHeal secures $5M in venture funding

CartiHeal (2009), Ltd, a privately held medical device company, focused on developing and bringing to market a proprietary, off-the-shelf, and cell-free cartilage regeneration technology, announced that it raised $5 million in venture funding from two US-Israeli venture capital firms, Accelmed and Access Medical Ventures. The financing will be used to prepare its first product launch early 2013 in Europe.

1 Feb 2012

Rensselaer professor wins CAREER Award from NSF

Ryan Gilbert, assistant professor in the Department of Biomedical Engineering at Rensselaer Polytechnic Institute, has won a prestigious Faculty Early Career Development Award (CAREER) from the National Science Foundation (NSF).

1 Feb 2012

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Roundtable discusses importance and potential benefits of palliative care in the ICU

If you think palliative care and the ICU don't go together, think again. The importance and potential benefits of palliative care to ease suffering and improve quality of life for patients being treated in hospital intensive care units (ICUs) has received increasing recognition but is not without significant challenges, as discussed in a Roundtable discussion in Journal of Palliative Medicine, a peer-reviewed journal published by Mary Ann Liebert, Inc.

1 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012